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ABSTRACT
During the last 10 years, multiple studies using reduced-intensity (RI) conditioning followed by allogeneic
stem cell transplantation (AlloSCT) have been reported in adult and, less so, pediatric recipients. RI AlloSCT
allegedly eradicates malignant cells through a graft-versus-leukemia/graft-versus-tumor effect provided by
alloreactive donor T lymphocytes, natural killer cells, or both. Various studies have clearly demonstrated a
graft-versus-leukemia/graft-versus-tumor effect in hematologic malignancies and solid tumors. Acute short-
term toxicity, including infection and organ decompensation after myeloablative conditioning therapy, can
result in a significant incidence of early transplant-related mortality. More importantly, long-term late
effects—including growth retardation, infertility, and secondary malignancies—are major complications after
myeloablative conditioning therapy, especially in vulnerable children, who are more susceptible to these
complications. Recent results comparing RI conditioning with myeloablative conditioning followed by HLA-
matched sibling AlloSCT have demonstrated a significant reduction in use of blood products, risk of infections,
transplant-related mortality, length of hospitalization, and feasibility of conditioning therapy in outpatient
settings. Despite the success of RI AlloSCT, large prospective randomized multicenter studies are necessary
to define the appropriate patient population, optimal conditioning regimens and pretransplantation immuno-
suppression, role of donor lymphocyte infusions, duration of hospitalization, overall survival, cost-benefit ratio,
and differences in long-term effects to evaluate the role of RI AlloSCT more fully. We review the recent
experience of RI AlloSCT in adults and children with both malignant and nonmalignant diseases and discuss
the challenges for the future.
© 2005 American Society for Blood and Marrow Transplantation
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Allogeneic hematopoietic stem cell transplant (Al-
oSCT) from related or unrelated histocompatible do-
ors has been well established as potentially curative
herapy for children and adults with selected hemato-
ogic malignancies [1]. The concept of AlloSCT as a
reatment option for hematologic malignancies has
ong been based on the assumption that myeloablative
oses of cytotoxic therapy were required for both
isease eradication and host immunosuppression. Sev- h
B&MTral observations, however, have challenged the
ogma that high-dose cytotoxic therapy was a sine qua
on for disease eradication with AlloSCT. These ob-
ervations include (1) decreased relapse rates in recip-
ents of AlloSCT compared with autologous or syn-
eneic stem cell transplants (SCT) [2]; (2) increased
isk of relapse after T cell–depleted compared with
nmodiﬁed allografts [3]; (3) decreased risk of relapse
n patients who develop acute or chronic graft-versus-
ost disease (GVHD) after allografting [4-10]; and (4)
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4emission induction after donor lymphocyte infusion
DLI) in some patients whose disease had relapsed
fter SCT [11-16]. Taken together, these observations
uggested that immune cell genetic disparities be-
ween donors and recipients also included graft-ver-
us-tumor (GVT) effects capable of eradicating the
nderlying host malignancy. These observations, in
ddition to better ways of controlling both host and
onor immune reactions, led to reassessment of strat-
gies for AlloSCT. Speciﬁcally, instead of eradicating
umors through intensive and, thereby, toxic chemo-
adiation, the SCT donor’s immune cells might be
sed for that purpose, relying on allogeneic GVT
ffects. Elimination of high-dose cytotoxic therapy
ould then allow elderly or medically inﬁrm patients
o be treated with SCT.
There is a substantial heterogeneity between var-
ous reduced-intensity (RI) conditioning regimens in
erms of dose of chemotherapy and radiotherapy and
egree of immunosuppression [17] (Figure 1). As a
orking deﬁnition, a truly nonmyeloablative regimen
hould not eradicate host hematopoiesis and should
llow relatively prompt hematopoietic recovery (28
igure 1. The most widely used preparative regimens in nonmy-
loablative stem cell transplantation and conventional transplanta-
ions. The aggressiveness of the underlying malignancy and the
onor-recipient genetic disparity, the recipient’s immunocompe-
ence, and sensitization are important in the decision-making pro-
ess for each clinical situation. MUD indicates matched unrelated
onor; CLL/LGL, chronic lymphocytic leukemia/low-grade lym-
homa; CML, chronic myelogenous leukemia; LCL, large-cell
ymphoma; AML, acute myelogenous leukemia; MM, multiple my-
loma; F-TBI 2 Gy, ﬂudarabine and total body irradiation (TBI) 2
y; FlagIda, ﬂudarabine, cytosine arabinoside, and idarubicin; MF,
elphalan and ﬂudarabine; BEAM, carmustine, etoposide, cytosine
rabinoside, and melphalan; Bu8/F/ATG, busulfan 8 mg/m2, ﬂu-
arabine, and antithymocyte globulin; TBICy, TBI and cyclo-
hosphamide; TBIFTT, TBI, ﬂudarabine, and thiotepa; Bu
6/Cy, busulfan 16 mg/m2 and cyclophosphamide; Bu/Flu, busulfan
escalated doses) and ﬂudarabine. *The immunosuppression re-
uired depends on the genetic disparity, immunocompetence, and
ensitization of the recipient. Reprinted with permission from
lsevier Ireland Ltd [17].ays) without a transplantation [18]. Upon engraft- t
04ent, mixed chimerism should be present. If the graft
s rejected, prompt autologous recovery should occur.
onversely, an ablative regimen requires hematopoi-
tic transplantation for recovery, and complete chi-
erism occurs upon engraftment. Many of the
educed-toxicity regimens referred to as nonmyelo-
blative have not been documented to meet these
riteria [19]. These regimens require a transplantation
or hematologic recovery, and if the graft is rejected,
rolonged aplasia typically occurs. These should be
eferred to as “reduced-toxicity” ablative regimens
20]. This distinction in intensity of regimens is cru-
ial to differentiate the graft-versus-leukemia (GVL)
ffects of donor engraftment from the antitumor ef-
ect of the conditioning regimen.
The theoretical reduction in incidence of acute
VHD after RI AlloSCT may be due to limited tissue
amage in the recipient. This may translate into de-
reased cytokine storm, which has been described af-
er myeloablative conditioning therapy to provide a
roinﬂammatory milieu for the development of acute
VHD [21,22]. Also, studies in animals have demon-
trated that the development of transient mixed do-
or-host chimerism may facilitate establishment of
utual tolerance, which, in turn, may downregulate
raft-versus-host (GVH) activity [23,24]. Several
ears ago, Storb et al. [25] and Georges et al. [26]
riginally demonstrated the ability to achieve mixed
nd, ultimately, complete donor chimerism after RI
onditioning (200 cGy) in dog leukocyte antigen–
dentical canine allogeneic transplant recipients and
ubsequently demonstrated the successful ability to
dminister DLI as potential adoptive cellular immu-
otherapy after RI conditioning in a similar animal
odel. Subsequently, the group from Israel [27] dem-
nstrated the initial early results of this approach in
umans with refractory hematologic malignancies
ith comorbid features. In this article, we review the
ecent experience of RI AlloSCT in adults and chil-
ren with both malignant and nonmalignant diseases
nd discuss the challenges for the future.
I AlloSCT FOR ADULT ACUTE MYELOID LEUKEMIA
ND MYELODYSPLASTIC SYNDROME
The median age of presentation in acute myeloid
eukemia (AML) is more than 60 years, and the ade-
uate management of AML in older patients remains
he major challenge. Because of an increase in comor-
idities such as infections and impaired organ func-
ion, the arbitrary age limit for intensive conditioning
herapy before allogeneic transplantation in patients
ith AML is between 50 and 55 years. RI AlloSCT
ight be one way to reduce the substantial treatment-
elated mortality of older patients and thus provide
he curative potential of allogeneic cell therapy. How-
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Reduced-Intensity Allogeneic Stem Cell Transplantation in Adults and Children
Bver, older patients with refractory or relapsed AML
ho receive nonmyeloablative SCT seem to have
apid recurrence and poor long-term survival. This
ay be because the GVL effect is less potent or
ecause the disease progresses too rapidly [28]. Simi-
arly, patients with myelodysplastic syndrome (MDS)
nd secondary AML were reported to have poor dis-
ase-free survival [29]. A certain amount of cytoreduc-
ion may be necessary for patients with MDS or re-
apsed or refractory AML. However, elderly medically
nﬁrm patients with AML in ﬁrst complete remis-
ion (CR1) who received a nonmyeloablative SCT
rom matched sibling donors seem to have survival
omparable to that with myeloablative SCT [30]
Figure 2).
Should an RI AlloSCT approach be extended rou-
inely to younger adults with AML in CR1 otherwise
ligible for conventional myeloablative SCT? Gorin
t al. [27] have demonstrated CR rates of 50% after RI
lloSCT in a younger cohort of patients with AML.
n most of the studies mentioned in Table 1, the
umber of patients enrolled in the studies was small,
tem cell donors were different, conditioning regi-
ens and pretransplantation and posttransplantation
mmunosuppression were variable, many of the stud-
es were single-center studies, and, most importantly,
ollow-up was short. With all of these issues, it is
ifﬁcult to compare various studies, and the results
hould be interpreted cautiously. There is a need for
ulti-institutional randomized trials to compare var-
ous factors that inﬂuence the outcome of RI Al-
oSCT. In the future, the role of consolidation with
emtuzumab ozogamicin after RI AlloSCT to eradi-
ate minimal residual disease should also be studied. Is
here any role for tailoring conditioning regimens
truly nonmyeloablative versus RI) according to cyto-
igure 2. Kaplan-Meier survival estimates of overall and progres-
ion-free survival for 18 patients with de novo or secondary AML in
R1 after nonmyeloablative SCT (2 Gy of total body irradiation
ith or without 90 mg/m2 of ﬂudarabine). Reprinted with permis-
ion from Blackwell Publishing [30].enetics, gene-expression proﬁling, or the proteomics i
B&MTf AML? Furthermore, routine molecular monitoring
f WT1 gene transcripts might be helpful for the
rediction and management of relapse after RI Al-
oSCT. Results from various studies [27-34] are sum-
arized in Table 1.
I AlloSCT FOR ADULT CHRONIC MYELOID
EUKEMIA
Although myeloablative allogeneic transplantation
s a curative therapy for chronic myeloid leukemia
CML), treatment-related mortality is still a major
ause of posttransplantation death, especially for pa-
ients older than 40 years. The rate of CR in response
o DLI has been impressive, with 70% to 80% of
elapsed CML patients achieving durable remissions
fter DLI [10,12,35-38]. Given the therapeutic role of
LI in patients with CML and considering the doc-
mented therapeutic potential of alloreactive donor
ymphocytes administered after bone marrow trans-
lantation in CML, it seems reasonable to exploit the
herapeutic use of alloreactive donor lymphocytes af-
er establishment of host-to-graft transplantation tol-
rance induced by engraftment of donor stem cells
fter RI conditioning. Because CML in chronic phase
s a rather indolent disease, it seems to be an ideal
isease to evaluate the RI AlloSCT approach. Patients
ith CML receiving RI AlloSCT in ﬁrst chronic
hase have very good overall survival (OS) and dis-
ase-free survival [39,40] (Figure 3). However, pa-
ients receiving RI AlloSCT in blast crisis seem to
ave a poor prognosis, which is also the case for
onventional myeloablative AlloSCT. Patients with
ML in blast crisis might beneﬁt from cytoreduction
efore RI AlloSCT.
The ﬁeld of CML therapy continues to change,
nd the question of to whom to apply the nonmyelo-
blative approach is problematic. Restricting the ther-
py to only those patients who experience treatment
ailure with imatinib or those who have a related or
nrelated donor but are too old or too ill for conven-
ional transplantation would conﬁne the treatment to
very small group of patients. One possible approach
ight be to add nonmyeloablative transplantations as
n immunologic adjuvant after initial cytoreduction
ith imatinib, followed by the addition of imatinib
fter transplantation to eradicate any residual disease.
arger studies are required to evaluate the role of RI
lloSCT in CML. Results from other studies [31,41-
4] are included in Table 2.
I AlloSCT FOR CHRONIC LYMPHOID LEUKEMIA
Most patients with chronic lymphoid leukemia
CLL) present in advanced age, and the relatively
ndolent course of the disease in a substantial propor-
405
Table 1. RI AlloSCT for Adult Patients with AML/MDS
Study n Disease/Status†
Median
Age, y
(Range) Donor Regimen
Acute GVHD
Prophylaxis
Myeloid and
Platelet
Recovery
(Median Day)
Donor
Chimerism*
(% Patients)
Incidence of
GVHD
OutcomeAcute Chronic
Gorin [27] 40 AML (32)/MDS (8)
CR1–12, CR2–8, RR-12
RAEB-8
NA (3–64) MUD
MRD
Bu/Flu/ATG or
Flu/low-dose TBI
CSP NA 100 47% NS CR-50%
Giralt [28] 31 AML (31)
1st CR-8
>1st CR-23
61 (21–74) MRD
MMRD
Flu/Ara-C/Ida
Ara-C/CDA
CSP/tacrolimus
 steroids
 MTX
13/17 65 19% NA 1-y OS-47%
1-y DFS-34%
Kroger [29] 37 AML (7)
MDS (30)
RA-5
RAEB-6
RAEBT-11
CMML-3
sRA-3
sRAEBT-2
sAML-7
55 (23–72) MUD
MRD
Flu/Bu/ATG CSP and MTX 14/14 80 37% 48% DFS-12%
Feinstein [30] 18 AML (18)
1st CR
59 (36–73) MSD Low-dose TBI or
Flu/low-dose TBI
CSP/MMF 4/0 80 45% 22% 1-y OS-54%
1-y PFS-42%
Giralt [31] 43 AML (43)
1st CR-1
>1st CR-5
RR-27
UR-10
52 (43–60) MRD
MMRD
MUD
Flu/Mel
Cladribine/Mel
Tacrolimus and MTX 14/21 100 39% 45% 2-y DFS-34%
Rezvani [32] 149 MDS (53)
PR/CR-23
AML (64) CR1 and 2–23, >CR2–41
ALL (36)
9 CR1, 10 CR2, 14 PR
51 (3–68) MSD
MUD
Flu-based CSP and MTX NA 77 43% NA OS-35%
Corradini [33] 12 AML (5)/MDS (6)
ALL (1)
CR1–3, >CR2–2, UR-4
RR-3
49 (20–68) MSD Flu/Thio/Cy CSP and MTX 13/15 88 45% 47.5% CR-75%
McSweeney [34] 13 AML (12)-CR1–6, CR >1–2
Induction failure-3
MDS-RAEBT-1
ALL(1)-CR3
60 (36–72) MSD Low-dose TBI CSP/MMF 11/11 92 47% 74% CR-45%
AML indicates acute myeloid leukemia; MDS, myelodysplastic syndrome; CR, complete remission; RR, refractory relapse; RAEB, refractory anemia with excess blasts; RAEBT, refractory anemia in
blast transformation; ALL, acute lymphoblastic leukemia; RA, refractory anemia; CMML, chronic myelomonocytic leukemia; sRA, secondary refractory anemia; sRAEBT, secondary refractory
anemia in blast transformation; sAML, secondary AML; UR, untreated relapse; PR, partial remission; MUD, matched unrelated donors; MRD, matched related donors; MMRD, mismatched related
donors; MSD, matched sibling donors; Bu, busulfan; Flu, ﬂudarabine; ATG, antithymocyte globulin; TBI, total body irradiation; Ara-C, cytosine arabinoside; Ida, idarubicin; CDA, cladrabine; Mel,
melphalan; Thio, thiotepa; Cy, cyclophosphamide; CSP, cyclosporine; MTX, methotrexate; MMF, mycophenolate mofetil; NS, not stated; myeloid recovery, absolute neutrophil count 500/L;
platelet recovery, 20 000/L; NA, not available; OS, overall survival; DFS, disease-free survival; PFS, progression-free survival.
*Any degree of donor chimerism.
†Number in parentheses represents number of patients with each discharge subtype.
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Bion of cases makes symptom palliation a reasonable
reatment goal in many cases. Nevertheless, approxi-
ately one third of the patients are younger than 60
ears old, and 10% to 15% are younger than 50 years.
n this group of patients, the aim of treatment cannot
erely be palliative. Young patients with poor-risk
LL requiring therapy should be offered experimen-
al therapies aimed at achieving cure. The beneﬁt of
llogeneic transplantation is potentially related to
VL effects, and prolonged remissions have been
eported in patients with advanced CLL receiving
igh-dose chemotherapy and allogeneic bone marrow
r peripheral blood stem cell (PBSC) transplantation
45]. However, high-dose myeloablative AlloSCT is
ssociated with substantial transplant-related mortal-
ty (TRM) (31% at 3 months; International Bone
arrow Transplantation Registry) [46]. A European
one Marrow Transplant Registry study comparing
I AlloSCT with conventional AlloSCT for CLL has
uggested that outcomes may be superior with an RI
pproach, and in this series, the cumulative TRM was
8% [47]. In a comparison of ablative versus nonab-
ative transplantations at M.D. Anderson Cancer Cen-
er, the long-term survival seems to be similar (ap-
roximately 40%) despite the higher age range of
onablative SCT patients who are minimal residual
isease negative and have longer disease-free intervals
ith improved OS than patients who remain minimal
esidual disease positive [48] (Table 2). Recently,
houri et al. [45] demonstrated GVL activity after RI
lloSCT in patients with persistent or progressive
isease by early taper and discontinuation of tacroli-
us followed by rituximab and DLI in patients who
id not develop GVHD. However, immunomanipu-
ation was associated with a high incidence of GVHD
60% chronic). Moreover, the natural history of re-
ponse to ﬂudarabine, cyclophosphamide, and ritux-
mab without allograft in CLL was not described in
he study [45].
igure 3. Kaplan-Meier survival estimates for 30 patients with
ML conditioned with low-dose single-exposure total body irradi-
tion. Reprinted with permission from the American Society for
lood and Marrow Transplantation [40].As yet, long-term follow-up information on RI f
B&MTlloSCT in CLL is limited. The role of RI AlloSCT
eeds to be clearly deﬁned for CLL patients. Patients
ho do not attain a CR with initial therapy or who
ave high-risk genetic abnormalities (ie, del[11q22-
23], del[17p13], unmutated somatic VH gene status,
nd p53 mutations) should be considered candidates
or RI AlloSCT in well-designed clinical trials. The
ole of rituximab and alemtuzumab in RI conditioning
egimens for CLL needs to be studied further. Results
rom other studies in CLL [45,49,50] are included in
able 2.
I AlloSCT FOR MULTIPLE MYELOMA
Autologous SCT after high-dose myeloablative
herapy has increased CR rates to 50% in patients
ewly diagnosed with myeloma, thus resulting in a
igniﬁcant increase in event-free survival and OS com-
ared with conventional therapy [51-53]. Although a
ubstantial fraction of patients remain alive and dis-
ase free for more than 10 years, the frequency of
isease progression or relapse continues to be high
fter transplantation, especially in patients with poor
rognostic features at presentation [52,54]. Although
yeloablative AlloSCT uses a stem cell source that is
ot contaminated with myeloma cells and induces a
raft-versus-myeloma effect [55], the survival rates
ave been inferior to those after myeloablative autol-
gous SCT because of high TRM [56-58]. However,
lloSCT is possibly the only genuinely curative ther-
py in multiple myeloma (MM). The RI AlloSCT
pproach is associated with less TRM while harness-
ng the GVT effect. A nonmyeloablative conditioning
egimen with melphalan 100 mg/m2 combined with
LIs has induced good disease control at 1 year but
ith a signiﬁcant rate of GVHD in 31 patients with
igh-risk MM [59] (Figure 4). Because early TRM is
educed with a nonmyeloablative conditioning regi-
en, this approach should be tested in frontline treat-
ent in older patients. However, preliminary RI Al-
oSCT studies in MM have clearly shown that results
re related to disease status, and the relapse rates are
igh in patients with advanced disease. Therefore,
educing tumor burden with autologous SCT before
I AlloSCT should be considered. The Seattle group
as reported results with autologous SCT followed by
onmyeloablative AlloSCT in 44 patients [60]. Al-
hough GVHD remains a problem, the feasibility of
his approach has been demonstrated. Kroger et al.
61] reported signiﬁcantly less transplant-related or-
an toxicity and an overall response rate of 90% after
I AlloSCT in MM patients who received allografts
rom matched unrelated donors. Results from most of
he studies are encouraging, but because the studies
re small, mostly single-center studies and because
ollow-up is still short, results should be cautiously
407
Table 2. R1 AlloSCT in Adults with Chronic Myeloid and Chronic Lymphocytic Leukemia
Study n Disease/Status
Median
Age, y
(Range) Donor Regimen
Acute GVHD
Prophylaxis
Myeloid and
Platelet
Recovery
(Median Day)
Donor
Chimerism*
(% Patients)
Incidence of
GVHD
OutcomeAcute Chronic
Giralt [31] 27 CML
1st CP-6
Blast phase-21
52 (43–60) MRD
MMRD
MUD
Flu/Mel Tacrolimus and MTX 14/21 100 39% 45% 1-y OS-32%
1-y DFS-34%
Or [39] 24 CML-1st CP 35 (3–63) MRD
MUD
Bu/Flu
Bu/Flu/ATG
CSP/MTX 16/3 100 75% 55% 5-y OS-85%
DFS-85%
Khoury [40] 30 CML-1st CP-28
Blast phase-2
47 (21–63) MSD Cy/low-dose TBI CSP 11/14 95 90% 92% 2-y OS-83%
Ehninger [41] 45 CML-1st CP-20
>1st CP-25
52 (25–65) MRD
MUD
Bu/Flu CSP  MMF  MTX
and steroids
14/17 74 65% NA 1-y OS-62%
1-y DFS-34%
Bornhauser [42] 44 CML
1st CP-26
AP-11
BC-7
52 (25–65) MRD
MUD
Bu/Flu CSP
CSP  MMF
CSP  MTX
8/5 99 61% NA DFS-41%
Barta [43] 36 CML
1st CP-26
AP-10
49 (15–59) MSD
MMSD
Ara-C/dibromomannitol CSP  MTX 15/29 94 25% 69% OS-83%
DFS-77%
Raiola [44] 15 CML
1st CP-9
AP-6
BC-2
52 (43–60) MSD Thio/Cy/ATG CSP  MTX 17/20 79 51% 45% OS-80%
Khouri [45] 17 CLL-1st relapse
(CS)-8
>1st relapse
(CRef)-7
Primary
refractory-2
54 (43.6–73) MSD Flu/Cy
Flu/Cy/rituximab
Tacrolimus and MTX 10/NA 100 41% 60% PFS-60%
Schetelig [49] 30 CLL
PR/CR (CS)-15
SD/PD
(CRef)-15
NA MSD
MUD
Bu/Flu/ATG CSP  MMF
CSP  MTX
18/15 NA 50% NA 2-y OS-79%
2-y PFS-61%
Dreger [50] 77 CLL
CR-8
PR-42
<PR-27
54 (30–66) MSD
MUD
Low-dose TBI
Low-dose TBI/Flu
Flu/alkylator  ATG 
alemtuzumab
CSP
CSP  MMF
CSP  MTX
12/NA 87 OS-72%
EFS-56%
CML indicates chronic myeloid leukemia; CP, chronic phase; AP, accelerated phase; BC, blast crisis; CLL, chronic lymphocytic leukemia; CS, chemosensitive; CRef, chemorefractory; PR, partial
remission; CR, complete remission; SD, stable disease; PD, progressive disease; NA, not available; MRD, matched related donors; MMRD, mismatched related donors; MUD, matched unrelated
donors; MSD, matched sibling donors; MMSD, mismatched sibling donors; Flu, ﬂudarabine; NA, not available; Mel, melphalan; Bu, busulfan; ATG, antithymocyte globulin; TBI, total body
irradiation; Ara-C, cytosine arabinoside; Thio, thiotepa; Cy, cyclophosphamide; MTX, methotrexate; CSP, cyclosporine; MMF, mycophenolate mofetil; myeloid recovery, absolute neutrophil count
500/L; platelet recovery, 20 000/L; OS, overall survival; DFS, disease-free survival; EFS, event-free survival; PFS, progression-free survival.
*Any degree of donor chimerism.
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Bnterpreted, as late relapses are common in MM. On-
oing multicenter studies are using genetic random-
zation to compare RI AlloSCT and a second autolo-
ous SCT in patients who have received a ﬁrst
utologous SCT. Also, randomized studies should be
erformed to compare RI AlloSCT with conventional
yeloablative AlloSCT. As the ﬁeld of MM therapy
ontinues to advance, the role of thalidomide, protea-
ome inhibitors, antisense bcl-2, and idiotype den-
ritic cell vaccination should be studied before or after
I AlloSCT. Results from other studies in MM [61-
6] are included in Table 3.
I AlloSCT FOR ADULT LYMPHOMA
AlloSCT theoretically provides several advantages
ver autologous SCT, including provision of a lym-
homa-free graft, reduced rates of secondary MDS
nd leukemia, and a potentially curative graft-versus-
ymphoma effect. Increasing evidence has accumu-
ated to support the concept of a therapeutically rel-
vant graft-versus-lymphoma effect for a number of
ymphoma subtypes, and a gradual improvement in
RM rates has made these approaches more attrac-
ive. RI approaches allow application to a broader
atient group, but follow-up in these studies is lim-
ted. In lymphoma, histology, chemosensitivity, and
rior transplantation are important prognostic factors
fter RI AlloSCT. Results for nonmyeloablative Al-
oSCT are particularly promising in low-grade non-
odgkin lymphoma (NHL), and the graft-versus-
ymphoma effect may augment response and delay or
revent relapse [67,68]. However, for aggressive dis-
ase, nonmyeloablative regimens should be indicated
nly for patients with minimal disease, because the
igure 4. Kaplan-Meier estimate of actuarial survival after allograf
isease status. Patients with responsive disease (RD; including CR a
lloSCT had signiﬁcantly better event-free survival and OS compa
utologous SCTs. Reprinted with permission from the American Sonmyeloablative regimens are unable to control the c
B&MTumor before the generation of a graft-versus-lym-
homa effect and/or lack the ability to control rapidly
roliferating disease [69]. Patients with aggressive dis-
ase may require a higher-dose regimen.
The role of RI AlloSCT in NHL is compromised
y the paucity of large clinical trials. There are no
andomized clinical trials of RI AlloSCT versus con-
entional myeloablative AlloSCT or autologous SCT.
ost reports include highly heterogeneous patient
ohorts with varying histologies (low-, intermediate-
nd high-grade NHL, as well as Hodgkin disease) and
arying stages of disease (from patients in ﬁrst CR to
hose in chemorefractory late relapse). The relative
erits of more or less intensive preparative regimens
or various histologies of NHL and of strategies that
ncorporate T-cell depletion need to be more clearly
eﬁned by more widespread collaborative studies.
here is also a need to deﬁne the role of monoclonal
ntibodies and radioimmunotherapy in the condition-
ng regimens in RI AlloSCT. Results from various
tudies in NHL [67-75] are included in Table 4.
NRELATED RI AlloSCT FOR OTHER HEMATOLOGIC
ALIGNANCIES
There are only a few studies evaluating unrelated
I AlloSCT for hematologic malignancies. Maris et
l. [76] demonstrated that matched unrelated adult
onor AlloSCT after RI conditioning for other hema-
ologic malignancies was feasible in patients ineligible
or conventional AlloSCT. PBSC RI AlloSCT con-
erred higher donor T-cell chimerism, greater durable
ngraftment, and better progression-free and OS
ompared with marrow RI AlloSCT. The incidence of
VHD (52%) and the 1-year OS rate (52%) were
rding to the number of prior myeloablative autologous SCTs and
tial response) receiving 1 myeloablative autologous SCT before RI
th patients with progressive disease (PD) and/or 2 myeloablative
of Clinical Oncology [59]. AT indicates autologous SCT.ts acco
nd par
red wiomparable to those with related RI AlloSCT. Re-
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Table 3. RI AlloSCT in Adults with Multiple Myeloma
Study n
Disease
Status
Median
Age, y
(Range) Donor Regimen
Acute GVHD
Prophylaxis
Myeloid and
Platelet
Recovery
(Median Day)
Donor
Chimerism*
(% Patients)
Incidence of
GVHD
OutcomeAcute Chronic
Badros [59] 31 PD-17
NCR-6
PR-5
CR2–3
56 (38–69) MSD
MUD
Mel
Flu/Mel/TBI
CSP
CSP  steroids
14/15 89 58% 33% 1-y OS-71%
Maloney [60] 44 CR-6
PR-22
UR-7
Ref-19
52 (29–71) MSD Low-dose TBI
Flu/low-dose TBI
CSP  MMF 0/0 100 38% 56% ORR-81%
Kroger [61] 21 PR-1
MR-1
NC-3
PD-8
50 (32–61) MUD Flu/Mel/ATG CSP  MMF
CSP  MTX
16/22 100 57% 37% ORR-90%
2-y EFS-74%
Lee [62] 45 >PR-14
<PR-34
52 (38–68) MSD
MUD
Mel
Mel/low-dose TBI/Flu
CSP
CSP  steroids
12/23 93 78% 58% 3-y OS-36%
Peggs [63] 20 CR-1
PR-18
MR-1
47 (34–58) MRD
MUD
MMUD
Flu/Mel/alemtuzumab CSP 45/52 95 155 10% 2-y OS-71%
Kroger [64] 17 PR-12
MR-3
NC-2
51 (32–64) MMRD
MUD
Flu/Mel/ATG CSP  MTX 16/23 100 38% 40% CR-73%
Giralt [65] 22 RR-8
SR-8
Pref-2
CR-1
51 (45–64) MSD
MUD
Flu/Mel Tacrolimus and MTX 12/14 80 72% 27% RR-72%
2-y PFS-19%
Mohty [66] 41 PR-29
CR-1
PD-11
52 (35–61) MSD Bu/Flu/ATG CSP
CSP  MTX
17/10 NA 43% 41% 2-y OS-62%
2-y PFS-41%
PD indicates progressive disease; NCR, near-complete remission; PR, partial remission; CR, complete remission; UR, untreated relapse; Ref, refractory disease; MR, minimal response; NC, no change;
RR, response rate; SR, chemosensitive relapse; Pref, primary refractory; MSD, matched sibling donors; MUD, matched unrelated donors; MRD, matched related donors; MMUD, mismatched
unrelated donors; MMRD, mismatched related donors; Mel, melphalan; Flu, ﬂudarabine; TBI, total body irradiation; ATG, antithymocyte globulin; Bu, busulfan; CSP, cyclosporine; MMF,
mycophenolate mofetil; MTX, methotrexate; myeloid recovery, absolute neutrophil count 500/L, platelet recovery, 20 000/L; NA, not available; OS, overall survival; ORR, overall response
rate; EFS, event-free survival; RR, refractory relapse; PFS, progression-free survival.
*Any degree of donor chimerism.
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Table 4. R1 AlloSCT in Adults with Lymphoma
Study n Disease
Disease
Status
Median
Age, y
(Range) Donor Regimen
Acute GVHD
Prophylaxis
Myeloid and
Platelet
Recovery
(Median Day)
Donor
Chimerism*
(% Patients)
Incidence of
GVHD
OutcomeAcute Chronic
Khouri [67] 10 Low-grade
lymphoma
SR-8
SD-2
50 (36–60) MSD Flu/Cy Tacrolimus  MTX 11/NA 80 10% 10% 16-mo PFS
and OS-
100%
Khouri [68] 20 Indolent
NHL
>CR2–12
PR-6
PD-2
51 (31–68) MSD Flu/Cy  rituximab Tacrolimus  MTX 11/NA 80 20% 64% CR-100%
Khouri [69] 15 Aggressive
lymphoma
RR-6
PR-6
55 (31–64) MSD Flu/Ara-C/cisplatin Tacrolimus  MTX NA 86 13% NS 1-y OS-60%
1-y PFS-40%
Faulkner [70] 65 Low- and high-
grade NHL,
MCL, PTCL
Good risk-13,
intermediate
risk-17, poor
risk-27,
unknown-8
45 (19–60) MSD
MMSD
MUD
BEAM/alemtuzumab CSP  MTX 15/15 63 26% 17% 2-y OS-68%
2-y EFS-58%
Carella [71] 15 NHL
HD
PR-6
1st relapse-2
>1st relapse-6
PR-1
36 (22–60) MSD Flu/Cy CSP  MTX 10/15 100 60% 13% CR-84%
Khouri [72] 18 MCL CR-8
PR-8
SD-2
56 (46–64) MSD
MMSD
MUD
Flu/Cy/rituximab
Flu/Ara-C/cisplatin
Tacrolimus  MTX 11/10.5 100 17% 36% CR-94%
3-y EFS-82%
Bishop [73] 15 Refractory NHL RR-10
Pri Ref-3
UR-1
SR-1
49 (33–63) MSD
MMSD
Flu/Cy CSP 9/10 100 71% 54% CR-60%
OS-57%
Anderlini [74] 6 Advanced HD RR-3
SR-3
29 (22–30) MSD
MUD
Flu based CSP or tacrolimus
 MTX
13/0 80 66% 50% CR-50%
Corradini [75] 17 PTCL UR-1
PD-2
>CR2–2
>PR2–12
41 (23–60) MSD
MMSD
MUD
Flu/Cy/thiotepa CSP  MTX 14/17 53 35% 50% 3-y OS-81%
3-y PFS-64%
NHL indicates non-Hodgkin lymphoma; MCL, mantle cell lymphoma; PTCL, peripheral T-cell lymphoma; HD, Hodgkin disease; SR, sensitive relapse; SD, stable disease; CR, complete remission;
PR, partial remission; PD, progressive disease; RR, refractory relapse; Pri Ref, primary refractory disease; UR, untreated relapse; MSD, matched sibling donors; MMSD, mismatched sibling donors;
MUD, matched unrelated donors; Flu, ﬂudarabine; Cy, cyclophosphamide; Ara-C, cytosine arabinoside; BEAM, carmustine, etoposide, cytarabine, and melphalan; MTX, methotrexate; CSP,
cyclosporine; myeloid recovery, absolute neutrophil count 500/L; platelet recovery, 20 000/L; NA, not available; NS, not stated; PFS, progression-free survival; OS, overall survival; EFS,
event-free survival.
*Any degree of donor chimerism.
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4ently, Sorror at al. [77] reported a retrospective anal-
sis of patients with various hematologic malignan-
ies, comparing severe toxicities and 1-year
onrelapse mortality after unrelated SCT after either
onablative or ablative conditioning regimens. Even
hough nonablative patients had signiﬁcantly higher
retransplantation comorbidity scores and were older,
hey experienced fewer grade III to IV toxicities than
blative patients. Furthermore, the incidence of grade
II to IV acute GVHD was signiﬁcantly lower in
onablative patients. The 1-year nonrelapse mortality
ate was 20% in nonablative patients compared with
2% in ablative patients. There is a need for large
linical studies comparing unrelated RI AlloSCT with
nrelated myeloablative AlloSCT for various hemato-
ogic and nonhematologic diseases and solid tumors.
I AlloSCT FOR ADULT SOLID TUMORS
The potential of immune GVT effects to control
dvanced solid tumors is documented in a nonalloge-
eic setting. Several ﬁndings justify AlloSCT for solid
umors because GVT effects can target tissue-speciﬁc
olymorphic antigens that are not derived from he-
atopoietic lineages. Some solid tumors are sensitive
o immunotherapy, such as renal cell carcinoma
RCC), melanoma, and ovarian cancer, and in theory,
ll carcinomas arising from epithelial tissues that are
argets of acute and chronic GVHD should be sus-
eptible to a GVT effect [78]. RI conditioning regi-
ens may provide a platform for antigen-speciﬁc im-
unotherapy directed against relevant tumor-
ssociated antigens. In a landmark article, Childs et al.
79] reported regression of metastatic RCC after non-
yeloablative allogeneic PBSC transplantation, with
ompelling evidence that regression of metastatic
CC was mediated by a GVT effect (Table 5). Re-
ently, Bishop et al. [80] reported on 16 patients with
rogressive metastatic breast cancer who were condi-
ioned with cyclophosphamide and ﬂudarabine before
I AlloSCT. Six patients had tumor regression at a
ime that was remote from the potential antitumor
ffects of cytotoxic chemotherapy in the transplanta-
ion conditioning regimen. These results suggest that
umor regression was associated with an immune-
ediated reaction related to AlloSCT. Results of non-
yeloablative SCT in patients with metastatic mela-
oma have thus far been disappointing. In an analysis
f 25 patients with metastatic melanoma undergoing
onmyeloablative SCT at 4 transplant centers, the
edian survival was only 100 days, and rapid disease
rogression was the major cause of death [81].
RI AlloSCT has been performed in patients with
arious other solid tumors, and responses have been
bserved in a minority of patients; moreover, these
esponses are partial and of relatively short duration
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Reduced-Intensity Allogeneic Stem Cell Transplantation in Adults and Children
Because of the rapid growth of these tumors and the
elay in occurrence of a GVT effect. Whether GVT
ffects might be more effective in patients with min-
mal residual disease, such as after autologous trans-
lantation or aggressive surgical debulking, should be
xplored. RI AlloSCT might be beneﬁcial to the pa-
ients who have slow-growing solid tumors. Recently,
garashi et al. [82] demonstrated enhanced suscepti-
ility of RCC and melanoma cells to natural killer
NK) cells with killer immunoglobulin receptor in-
ompatibility; this suggests that the NK cell–mediated
ntitumor effects seen against AML after killer immu-
oglobulin receptor–incompatible mismatched allo-
eneic transplantation might be induced in a similar
ashion against selected solid tumors. Results from
ther solid-tumor studies [83-87] are included in Ta-
le 5.
I AlloSCT FOR AUTOIMMUNE DISORDERS
Animal models of autoimmune disease, such as
ystemic lupus erythematosus and rheumatoid arthri-
is, have shown that AlloSCT may be superior to
utologous SCT, with higher cure rates and protec-
ion from disease progression, relapse, or both [88-
1]. The rationale for investigating AlloSCT for med-
cally refractory autoimmune diseases includes in part
he following: (1) elimination or suppression of auto-
eactive clones, (2) elimination or suppression of ma-
ernal-fetal microchimerism, (3) amelioration of auto-
mmune cytopenias, or (4) development of adoptive
llogeneic cellular immunotherapy and graft-versus-
utoimmune effect [92].
There have been several reports of myeloablative
lloSCT performed in patients with malignant and
onmalignant diseases who had a concomitant auto-
mmune disease. Hinterberger et al. [93] previewed
he data on patients who received AlloSCT for blood
isorders (n  30) with concomitant autoimmune
isease. Nineteen who developed GVHD achieved
emission. There are only a few case reports of suc-
essful RI AlloSCT in patients with autoimmune dis-
rders (psoriasis and rheumatoid arthritis) [94,95].
he RI AlloSCT approach is appealing for refractory
utoimmune diseases because of lesser transplant-re-
ated morbidity and mortality. Further studies are
eing conducted to deﬁne the role of RI AlloSCT for
utoimmune disease. We have received an investiga-
ional new drug permit from the Food and Drug
dministration (BB-IND 11093) to study RI AlloSCT
or selected medically refractory autoimmune diseases
systemic lupus erythematosus, rheumatoid arthritis,
ystemic scleroderma, and juvenile idiopathic arthri-
is). w
B&MTI AlloSCT IN CHILDREN
Socié et al. [96] reported long-term survival and
ate effects after allogeneic bone marrow transplanta-
ion in 6691 patients who were free of their original
isease for at least 2 years after AlloSCT. A large
umber of patients died of other secondary complica-
ions, including GVHD (31%), infection (6%), sec-
ndary malignancies (6%), and organ failure (6%).
hildren with nonmalignant disease who require my-
loablative AlloSCT for curative intent face the
bove-mentioned long-term late complications asso-
iated with this therapy: the risks of growth failure,
onadal failure, secondary malignancies, and second-
ry MDS weigh heavily on the decision to proceed
ith curative-intent therapy. It remains to be deter-
ined whether a select group of children receiving RI
onditioning therapy and AlloSCT will beneﬁt from a
educed risk of disease recurrence and, at the same
ime, a reduced risk of long-term complications.
The historical experience of myeloablative Al-
oSCT in patients with sickle cell disease (SCD) or
-thalassemia major indicates that stable mixed hema-
opoietic chimerism may be sufﬁcient to cure these
emoglobinopathies [97,98]. Thus, myeloablation per
e may not be mandatory for the treatment of SCD,
nd this raises the possibility that RI conditioning
egimens could be investigated as an alternative
ethod to reduce long-term complications in this
ubpopulation. Studies in a murine model of SCD
uggest that this approach could even be curative in
he HLA-disparate setting [99]. Given the preliminary
esults of reduced acute toxicity after RI AlloSCT, this
pproach seems attractive for patients with SCD, par-
icularly older patients and those with acquired organ
oxicity, and it may offer children the potential to
etain gonadal function and normal fertility. Iannone
t al. [100], in a prospective multicenter study, de-
cribed a nonmyeloablative SCT approach in 7 pedi-
tric patients with SCD (n  6) and thalassemia (n
1) who received pretransplantation ﬂudarabine and
00 cGy of TBI with or without antithymocyte glob-
lin. Regimen-related toxicity was minimal but re-
ulted in only transient donor engraftment in 6 of 7
atients. These preliminary results suggest that more
ntensive conditioning is required for previously trans-
used patients with hemoglobinopathies than 2 Gy of
otal body irradiation and ﬂudarabine (Table 6).
Mixed or complete donor chimerism achieved af-
er RI AlloSCT can potentially alter the natural his-
ory and outcome of patients with nonmalignant dis-
ases and spare them from short-term and possibly
ong-term toxicities. Amrolia et al. [101] used a non-
yeloablative approach with ﬂudarabine, melphalan,
nd antithymocyte globulin for 2 patients with severe
ombined immunodeﬁciency disease and 6 patients
ith other immune deﬁciencies. Seven of 8 patients
413
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4ere reported to survive from 8 to 17 months after RI
lloSCT (Table 6). The nonmyeloablative SCT ap-
roach permits rapid engraftment from sibling and
nrelated donors with minimal toxicity, even in the
resence of severe organ dysfunction, thus establish-
ng host tolerance to the donor immune cells respon-
ible for immune reconstitution. This regimen may
rove useful for patients who are ineligible for con-
entional SCT. Long-term follow-up is needed before
his approach is extended to patients at standard risk.
orwitz et al. [102] reported the results of a strategy
hat used a highly immunosuppressive but nonmy-
loablative regimen in 10 patients with chronic gran-
lomatous disease and a history of life-threatening
nfections. Donor chimerism was established in 9 of
he 10 patients, and 8 patients had circulating oxidase-
ositive phagocytes at follow-up (Table 6). The ques-
ion of whether a 30% mortality rate is acceptable
ust be asked. With the advent of modern antimicro-
ial prophylaxis and treatment, these children are
hriving [103], and more aggressive treatments, such
s bone marrow transplantation, are debatable in this
isease.
We recently reported the preliminary results in 21
hildren who received RI AlloSCT [104]. Our study
opulation included 14 patients with malignant and 7
atients with nonmalignant disease who were condi-
ioned with ﬂudarabine-based regimens. Sixteen of 21
atients showed evidence of myeloid engraftment.
hree primary and 2 secondary graft failures occurred
n patients with -thalassemia, hemophagocytic lym-
hohistiocytoses, MDS, and severe aplastic anemia.
he 1-year OS for good-risk versus poor-risk patients
International Bone Marrow Transplantation Registry
riteria) was 88.9% versus 38.9%, respectively. These
esults, however, include a heterogenous group of
atients with different donor sources and different RI
onditioning regimens. These preliminary results
hould be interpreted with caution until larger groups
f children with a homogenous diagnosis, cell source,
nd RI regimen are used. It remains to be determined
hat degree of intensity is required for different pe-
iatric subpopulations. Patients with primary refrac-
ory hematologic disease, including hemoglobinopa-
hies, MDS, hemophagocytic lymphohistiocytoses, or
evere aplastic anemia, may require more intense non-
yeloablative conditioning and immunosuppression
o prevent graft rejection. Also, the small dose of stem
ells in cord blood units might be a factor in graft
ejection, and combining cord blood units might im-
rove engraftment. Because transplant-related mor-
idity after RI AlloSCT is low, in these patients with
raft failure, a second AlloSCT with a myeloablative
egimen may be feasible. To accurately determine the
ifference, if any, of late long-term effects in pediatric
ecipients after RI AlloSCT, studies in selected patientpopulations with much longer follow-up are required.Ta Ia
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Besults from other pediatric studies [105-107] are
eported in Table 6.
NFECTIOUS COMPLICATIONS AFTER RI AlloSCT
The potential mechanisms of reduced infectious
orbidity after RI AlloSCT include decreased dura-
ion of severe neutropenia, reduced grade of mucosi-
is, enhanced immune reconstitution, and decreased
ates of severe acute GVHD [108,109]. Data on in-
ections in nonmyeloablative SCT recipients are pre-
iminary, and differences in the degrees of myeloab-
ation may lead to considerable variation in outcomes.
unghanss et al. [110] reported the results of a
atched pair analysis of 56 RI AlloSCT recipients and
ompared the rates of various infections with 112
ontrols who had received myeloablative AlloSCT.
acterial infections during the ﬁrst 30 days, however,
ere signiﬁcantly reduced in RI AlloSCT recipients
9% versus 27%; P  .01), with a trend toward a
eduction during the ﬁrst 100 days after RI AlloSCT
27% versus 41%; P  .07). In a subgroup analysis,
nfections commonly observed during periods of mu-
ositis (gram-negative bacteria, streptococci, and en-
erococci) were signiﬁcantly fewer in RI AlloSCT re-
ipients. In the same matched cohort study [110], RI
lloSCT recipients seemed to have equivalent risks
or aspergillosis compared with recipients after my-
loablative AlloSCT (15% versus 9%; median follow-
p, 12.7 months). There seems to be a trend, however,
oward an increased 1-year survival after aspergillosis
n RI AlloSCT recipients (63%). Identiﬁed risk factors
or developing cytomegalovirus (CMV) disease in-
lude lymphopenia and the CMV serologic status of
he donor and recipients [111,112]. Junghanss et al.
110] reported that CMV-positive recipients of RI
lloSCT showed trends toward a lower incidence of
MV antigenemia, CMV viremia, and CMV disease
uring the ﬁrst 100 days after transplantation com-
ared with the myeloablative AlloSCT group and that
MV disease occurred signiﬁcantly later among RI
lloSCT patients. Use of alemtuzumab for immuno-
uppression before RI conditioning can also increase
he risk of CMV infection. Chakrabarti et al. [113]
eported a 50% incidence of CMV infection at a
edian of 27 days after nonmyeloablative SCT with a
robability of 84.8% in patients at risk of CMV in-
ection. The results of the infectious disease reported
rom small studies should be veriﬁed in multiple larger
tudies, especially considering the substantial variation
etween conditioning regimens. This information will
e critically important to guide the development of
ational preventative strategies in RI AlloSCT recip-
ents. t
B&MTCUTE GVHD AFTER RI AlloSCT
The immune reconstitution after RI AlloSCT dif-
ers from myeloablative SCT in several important
spects. First, RI AlloSCT conditioning seems to
ause only limited tissue damage. Second, develop-
ent of transient mixed donor-host chimerism may
acilitate establishment of mutual tolerance, which, in
urn, may downregulate GVH activity [23,24]. Third,
he type and duration of immunosuppressive agents
dministered after RI AlloSCT conditioning may suf-
ciently differ from those used after myeloablative
lloSCT [108,109,114]. Fourth, the number and
unction of recipient antigen-presenting cells (APCs)
ay be higher after RI AlloSCT as compared with
yeloablative AlloSCT. These cells may play a major
ole in the initiation of GVH responses early after
CT [115,116]. The net clinical effects of these fun-
amental differences between nonablative and my-
loablative allogeneic conditioning regimens on the
ncidence or severity of GVHD remain to be deﬁned.
ielcarek et al. [117] retrospectively analyzed data
rom 2 age-matched cohorts of patients who had re-
eived either nonablative or myeloablative AlloSCT
rom HLA-matched related and unrelated donors.
he cumulative incidence of grade II to IV acute
VHD at day 100 after matched related donor
llografting was signiﬁcantly lower among RI Al-
oSCT recipients than among myeloablative recipi-
nts (P  .02), but there was no difference in the
umulative incidences of grade III or IV acute GVHD
r extensive chronic GVHD between the 2 groups.
fter unrelated donor allografting, the cumulative in-
idences of both grades II to IV and grades III and IV
cute GVHD at day 100 were lower among RI
lloSCT recipients than among myeloablative trans-
lant recipients (P .01; Figure 5), but the cumulative
ncidence of extensive chronic GVHD was not signif-
cantly different. The cumulative incidence rates of
eath with manifestations of GVHD during treatment
ere 35% and 24% at 15 months for the myeloabla-
ive and RI AlloSCT groups, respectively (P  .27);
eaths tended to occur later in the RI AlloSCT group.
HRONIC GVHD AFTER RI AlloSCT
Because the length of follow-up is relatively short,
t is difﬁcult to accurately assess the incidence and
everity of chronic GVHD after RI AlloSCT. How-
ver, studies from many centers [20,118,119] have
eported that the incidence of extensive chronic
VHD is at least comparable or higher for patients
ho undergo nonmyeloablative regimens as compared
ith conventional myeloablative allografting. Several
actors seem to predispose nonmyeloablative recipi-
nts to be at increased risk for chronic GVHD. First,
he population that receives these less toxic regimens
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4s generally older, and older age is more permissive for
evelopment of chronic GVHD. A second factor is
hat PBSCs, as compared with bone marrow, are the
referred graft source. Studies comparing the out-
ome of myeloablated recipients who received PBSC
ransplants versus bone marrow demonstrated consis-
ent trends toward higher cumulative incidences of
hronic GVHD in recipients of PBSCs [120-122].
eripheral blood is the preferred graft source for non-
yeloablative transplantations because it contains sig-
iﬁcantly more hematopoietic stem and progenitor
ells. Both of these cell populations are required to
chieve durable and robust allogeneic hematopoietic
ell engraftment. Graft content is particularly impor-
ant for nonmyeloablative regimens because higher
esistance to engraftment is encountered. As com-
ared with myeloablated recipients, nonmyeloablated
atients retain more recipient hematopoietic and lym-
hoid elements, both of which contribute signiﬁcantly
o resistance to engraftment. A third reason that
hronic GVHD may become more prevalent in non-
yeloablated recipients is due to the use of DLI.
ecause RI AlloSCT principally relies on GVT activ-
ty to control malignancies, DLI is one of the ﬁrst
herapeutic maneuvers considered when a stably en-
rafted patient has evidence of disease persistence,
rogression, or relapse. A prior clinical study examin-
ng 140 patients who relapsed after AlloSCT showed
hat chronic GVHD developed in roughly 60% of
atients who underwent DLI as salvage treatment
10]. Perhaps of greater signiﬁcance is the observation
hat chronic GVHD occurred in 80% of DLI pa-
ients who responded to treatment [10]. A fourth po-
ential and as yet unexplored variable is the effect that
esidual host populations have on GVHD pathogen-
sis. As compared with conventional myeloablative
egimens, nonmyeloablative conditioning spares more
igure 5. Cumulative incidences of acute GVHD after nonmyeloab
onor transplantation. B, Unrelated donor transplantation. Reprintecipient immune cells. Cellular interactions that are e
16ikely to be affected by these differences include donor
nd surviving host T lymphocytes with APCs and
ymphocyte regulatory circuits. Studies in mice sug-
est that such a recipient population induces a patho-
enic response, because elimination of host APCs,
ost CD4 cells, or both abrogates the development
f GVHD [115,123]. A ﬁfth potential variable is that
he tolerance induced by mixed chimera may reduce
hronic GVHD, and, ﬁnally, the incidence of chronic
VHD may vary between different RI regimens be-
ause of the difference in kinetics of engraftment.
etter understanding and further development of im-
unosuppressive drugs might result in better treat-
ent of GVHD. This in turn could lead to the more
idespread use of RI AlloSCT for the treatment of
atients with malignant and nonmalignant diseases.
MMUNE RECONSTITUTION AND BIOLOGICAL
ORRELATES OF ENGRAFTMENT AFTER RI AlloSCT
The immune system of patients after myeloabla-
ive AlloSCT is characterized by impaired immuno-
ogic responses to recall antigens as well as to mito-
enic or allogeneic stimuli, and this predisposes them
o various infections. Morecki et al. [124] demon-
trated that patients who received RI AlloSCT fea-
ured early recovery of the T cell–dependent mito-
enic response and non–major histocompatibility
omplex–restricted cytotoxicity when compared with
yeloablative AlloSCT. Similarly, Mohty et al. [125]
emonstrated an early recovery of leukocytes, CD8,
K lymphocytes, and circulating dendritic cells.
owever, in both of these studies, the number of
atients was small, and immune reconstitution was
ompared with that of historical controls. Random-
zed studies can answer whether early immune recov-
onditioning compared with myeloablative conditioning. A, Related
permission from the American Society of Hematology [117].lative cry can translate into a decrease in the risk of infec-
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Bion. Moreover, in most of the studies shown in
ables 1 to 6, myeloid and platelet engraftment is
aster than conventional myeloablative SCT to the
xtent that some patients do not have a nadir absolute
eutrophil count 500/L or a platelet count
20 000/L. Faster myeloid and platelet engraftment
ay result in a decreased incidence of mucositis and
ebrile neutropenia and also a decrease in use of blood
roducts and length of hospital stay [34]. Many cen-
ers are now performing RI AlloSCT in the outpatient
etting [34,126].
Monitoring the levels of donor chimerism among
he peripheral blood cell subpopulation after RI Al-
oSCT might help identify patients at risk for graft
ejection, acute GVHD, and relapse. Only a few re-
orts to date have analyzed the engraftment kinetics of
peciﬁc hematopoietic lineages after RI AlloSCT and
valuated the effect of the kinetics and degree of
onor chimerism on outcome. Childs et al. [127] stud-
ed chimerism evolution in 15 patients conditioned
ith cyclophosphamide and ﬂudarabine. Full donor
himerism was achieved earlier among T cells than
mong granulocytes, and the progression to full donor
-cell chimerism preceded GVHD and antitumor re-
ponses. Baron et al. [128] recently reported that ear-
ier establishment of donor NK cell chimerism was
ssociated with improved progression-free survival.
UTURE DIRECTIONS AND CHALLENGES
Although RI AlloSCT alone is unlikely to cure
ost patients with metastatic solid tumors, these pilot
tudies have been invaluable because they have pro-
ided important proof of concept of the therapeutic
otential of the GVT effect. On the basis of these
bservations, second-generation regimens that incor-
orate strategies to cytoreduce tumors before trans-
lantation (eg, autologous transplantation followed by
I AlloSCT, surgical or chemotherapeutic debulking,
r targeted small molecules) and methods to target the
onor immune system will likely be forthcoming. In-
reased understanding of tissue-speciﬁc polymorphic
inor histocompatibility antigens might lead to the
evelopment of vaccines that could be used to direct
he donor cytotoxic T cells toward tumor targets
ather than the typical tissues involved in GVHD.
argets include antigens present on both malignant
nd nonmalignant marrow cells and possibly even
olymorphic antigens present on certain metastatic
olid tumors.
Many issues remain to be addressed regarding how
o perform RI AlloSCT for various hematologic and
onhematologic malignancies. Conditioning regi-
ens used in different studies vary from minimally
blative (low-dose total body irradiation) to almost
yeloablative. Randomized studies should be per- (
B&MTormed to compare various regimens and pretrans-
lantation immunosuppression for speciﬁc malignant
nd nonmalignant diseases. Similarly, there is a need
o report engraftment status and donor chimerism in
uniform fashion so that meaningful comparisons can
e made. Measuring the levels of peripheral blood NK
ell subset donor chimerism may provide useful infor-
ation on RI AlloSCT outcomes and might allow
arly therapeutic interventions to prevent graft rejec-
ion or disease progression. After RI AlloSCT, serial
haracterization of donor chimerism might offer the
ossibility of identifying patients who are at the high-
st risk of developing relapse and who can be rescued
y immunotherapy.
Regardless of the technical approaches to RI Al-
oSCT, there is a fundamental requirement that con-
rolled clinical trials be performed with well-deﬁned
ematologic and nonhematologic malignancies to
valuate the role of RI AlloSCT more fully. Although
ost patients reported so far were heavily pretreated
nd often had chemoresistant disease, these patients
ay not be ideal for controlled trials because of the
ack of alternative therapies. More appropriate would
e the patients with hematologic and nonhematologic
alignancies who have experienced treatment failure
ith initial therapies, who have a poor prognosis, and
or whom salvage therapies exist that might be used
or comparison against RI AlloSCT. Finally, curative
reatment modalities work best when used early in the
isease course, and this strategy likely will also apply
o RI AlloSCT. This consideration must be balanced
y the fact that treatment-related mortality with RI
lloSCT is signiﬁcant and exceeds that of other fre-
uently used therapies. One might anticipate that
echnical reﬁnements and use in patients with earlier-
tage disease will enhance the safety of RI AlloSCT
nd thus increase acceptance of this modality for fu-
ure clinical trials. There has been a proliferation of
eports of RI AlloSCT in both adults and, more re-
ently, children with both malignant and nonmalig-
ant disease in phase I and phase II pilot studies. We
re now at the end of the beginning of RI AlloSCT as
therapeutic modality, and the future should be more
ocused with hypothesis-driven translational studies to
romote an increased understanding of the full poten-
ial of this therapeutic concept.
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